Direct Connections-Interviews
In this episode of Direct Connections, presented by IHSE, host Ben Thomas and his guests Dan Holland, a Marketing Manager with IHSE, and Dan Gundry, the Senior Director of LVX Sales at Barco, shed light on the expanding applications of IHSE’s technologies beyond the broadcast world into security, command, and control room environments. The…
Latest
Direct Connections
Vizrt and IHSE: A Partnership Powering Seamless Visual Storytelling
In a recent chat at NAB 2023, Chris Black, Global Head of Branding Communications at Vizrt, lauded the company’s partnership with IHSE USA to power seamless visual storytelling. Vizrt, a leading provider of innovative visual storytelling tools, relies on IHSE’s KVM systems for high-stress, high-performance environments like live broadcast centers and trade shows. Black…
Direct Connections-Interviews
Demystifying Display Management for Live Events
A panel discussion with leaders in esports, international event teleproduction, and KVM innovation discuss how KVM has made them more efficient, more productive.
Direct Connections-Interviews
At the Forefront of eSports: IHSE USA
IHSC USA, a leader in display solutions, provides eSports the latest and greatest high-end computer extender tech. Capabilities provide a real world stadium experience no matter where your virtual experience takes your audience.
Direct Connections-Interviews
VuWall: Our Video Solutions
IHSC uses customer feedback to enhance our video wall management software, TRX. With TRX, users can easily send any information to any display in their organization using a drag-and-drop interface. We have integrated with IHSC’s KVM switch based on customer input. Our goal is to simplify content management further, and our control panel enables…
Latest
Analyzing the Suppressive TME in In Vitro Based Assays
In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…
Targeting T Cells Within the Cancer Immunity Cycle
As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…
Inside Oncology Drug Development: Overcoming Resistance with Science
In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…
